Vaxxinity Advances Cholesterol Vaccine

A vaccine that could lower LDL cholesterol levels in the blood could soon be a reality for the nearly 94 million adults over the age of 20 who have borderline or high cholesterol. Vaxxinity, Inc. (Nasdaq: VAXX) has published data from multiple studies demonstrating that its vaccine candidate, VXX-401, reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results were published in the February 2024 edition of the Journal of Lipid Research.

Mei Mei Hu, CEO of Vaxxinity, commented, “Vaxxinity is committed to providing scalable, accessible, game-changing solutions for worldwide heart health. Despite multiple approved medications for LDL-C reduction, heart disease remains the number one killer in the world. A cholesterol vaccine like VXX-401 may provide a cost-effective and widely deployable solution that could potentially benefit hundreds of millions of people at risk. A well tolerated intervention that people can start early in life, and remain on for many years, lowering the cholesterol ‘area under the curve,’ has the potential to help us win the fight against heart disease.”

VXX-401 is currently in a Phase 1 clinical trial for safety and tolerability with initial topline data expected in mid-2024.


Vaxxinity believes these clinical results support the continued development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease.

VXX-401 was designed using Vaxxinity’s proprietary synthetic peptide vaccine platform and is being developed for the treatment of hypercholesterolemia.

Vaxxinity’s candidate is designed to induce robust, long-acting antibodies against PCSK9 and lower LDL cholesterol to prevent or treat coronary heart disease.

High LDL-C is a major risk factor for coronary heart disease, heart attack, and stroke, and atherosclerosis is the leading cause of disease burden globally.

Share This Article


About the Author

Vaxxinity Advances Cholesterol Vaccine

Catie Corcoran

Biotech Editor